Alpha 2.0
Login Register
» Articles » PMID: 29984265

Vismodegib-resistant Basal Cell Carcinomas in Basal Cell Nevus Syndrome: Clinical Approach and Genetic Analysis

Overview
Journal JAAD Case Rep
Specialty Dermatology
Date 2018 Jul 10
PMID 29984265
Citations 13
Authors
Kelly A E Sinx
Guido M J M Roemen
Virrie van Zutven
Renske Janssen
Ernst-Jan M Speel
Peter M Steijlen
Michel van Geel
Klara Mosterd
Affiliations
Soon will be listed here.
Citing Articles

Case report: Sequential treatment strategy for advanced basal cell carcinoma in Gorlin-Goltz syndrome: integration of vismodegib, radiotherapy, surgery, and high-intensity focused ultrasound.

Calik J, Oslizlo M, Slocka-Romaniuk B, Elsaftawy A, Sauer N Front Oncol. 2024; 14:1428702.

PMID: 39091908 PMC: 11291366. DOI: 10.3389/fonc.2024.1428702.

Sustained Suppression of Gorlin Syndrome-Associated Basal Cell Carcinomas with Vismodegib or Sonidegib: A Case Series.

Wescott R, Samlowski W Curr Oncol. 2023; 30(10):9156-9167.

PMID: 37887561 PMC: 10604938. DOI: 10.3390/curroncol30100661.

Personalized Systemic Therapies in Hereditary Cancer Syndromes.

Mastrodomenico L, Piombino C, Ricco B, Barbieri E, Venturelli M, Piacentini F Genes (Basel). 2023; 14(3).

PMID: 36980956 PMC: 10048191. DOI: 10.3390/genes14030684.

Patched Homolog 1 (PTCH1) Mutation in a CIC-Rearranged Sarcoma: Lack of Response to the Smoothened (SMO) Vismodegib.

Wu D, Murugan P, Skubitz K Cureus. 2023; 15(1):e34281.

PMID: 36843760 PMC: 9957587. DOI: 10.7759/cureus.34281.

Novel Approaches in Non-Melanoma Skin Cancers-A Focus on Hedgehog Pathway in Basal Cell Carcinoma (BCC).

Chmiel P, Klosinska M, Forma A, Pelc Z, Geca K, Skorzewska M Cells. 2022; 11(20).

PMID: 36291078 PMC: 9601130. DOI: 10.3390/cells11203210.

References
1.
Bresler S, Padwa B, Granter S . Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome). Head Neck Pathol. 2016; 10(2):119-24. PMC: 4838974. DOI: 10.1007/s12105-016-0706-9. View
2.
Epstein E . Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008; 8(10):743-54. PMC: 4457317. DOI: 10.1038/nrc2503. View
3.
Dreno B, Kunstfeld R, Hauschild A, Fosko S, Zloty D, Labeille B . Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. Lancet Oncol. 2017; 18(3):404-412. DOI: 10.1016/S1470-2045(17)30072-4. View
4.
Toguchida J, Yamaguchi T, Dayton S, Beauchamp R, Herrera G, Ishizaki K . Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med. 1992; 326(20):1301-8. DOI: 10.1056/NEJM199205143262001. View
5.
Atwood S, Sarin K, Whitson R, Li J, Kim G, Rezaee M . Smoothened variants explain the majority of drug resistance in basal cell carcinoma. Cancer Cell. 2015; 27(3):342-53. PMC: 4357167. DOI: 10.1016/j.ccell.2015.02.002. View